stockportfolio.pro
Stocks / GRDN vs IDYA
GRDN vs IDYA
Guardian Pharmacy Services, Inc. and IDEAYA Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Guardian Pharmacy Services, Inc. (GRDN) | IDEAYA Biosciences, Inc. (IDYA) | |
|---|---|---|
| Market cap | $2.7B | $2.8B |
| Revenue (latest FY) | $1.45B | $218.71M |
| Net income (latest FY) | $49.22M | $-113.70M |
| Revenue growth (5y CAGR) | 16.8% | 62.1% |
| Net margin | 3.4% | -52.0% |
| Return on equity | 23.9% | -11.1% |
| P/E ratio | 50.1 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GRDN — free Open IDYA — freeFrequently asked questions
Which is bigger, GRDN or IDYA?
IDEAYA Biosciences, Inc. is larger by market capitalization — $2.8B versus $2.7B.
Which grows faster, GRDN or IDYA?
Over the last five fiscal years, IDEAYA Biosciences, Inc. grew revenue faster — 62.1%/yr versus 16.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.